• Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press releases
  • Suppliers
  • Contact
  • Skip to main content
  • Skip to footer

Atara Biotherapeutics

  • About
    • Company
    • Management Team
    • Board of Directors
    • Collaborators
    • Contact
  • Technology
  • Pipeline
    • Atara Pipeline
    • Tab-cel
    • ATA188
    • ATA2271/ATA3271
    • ATA3219
  • Patients
    • Mission to Serve Patients
    • Clinical Studies
    • Expanded Access
    • Request Information
    • PTLD Champions
    • Multiple Sclerosis
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Join Our Team
    • Life at Atara
    • Explore Career Opportunities
    • Tech Ops
    • Job Search
  • Medical Professionals
  • Suppliers
  • Press Releases
  • Contact
  • LinkedIn
  • Twitter
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Quote
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact The Board
  • News
  • Careers

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 07, 2018 5:20pm EDT

Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer

Jun 07, 2018 8:00am EDT

Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

May 29, 2018 4:05pm EDT

Atara Biotherapeutics to Present Long-Term Tab-celâ„¢ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association

May 17, 2018 9:00am EDT

Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress

May 08, 2018 7:05am EDT

Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases

May 08, 2018 7:00am EDT

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 07, 2018 5:30pm EDT

Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development

May 07, 2018 8:00am EDT

Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe

May 01, 2018 8:00am EDT

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 09, 2018 4:45pm EDT
RSS
  • Prev
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...22
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed

    Footer

    • LinkedIn linkedin
    • Twitter twitter
    © 2021 Atara Biotherapeutics, Inc. All Rights Reserved
    • Privacy Policy
    • Sitemap

    This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy


    OK